SCHEDULE 13G/A: Jennison Associates Discloses 9.6% Stake in Arcutis Biotherapeutics

Jennison Associates LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 9.6% in Arcutis Biotherapeutics Inc. as of March 31, 2025.

Summary

• Jennison Associates LLC, an investment adviser, reported beneficial ownership of 11,360,875 shares of Common Stock in Arcutis Biotherapeutics Inc.
• This ownership represents 9.6% of the total class of securities.
• Jennison Associates LLC holds sole voting power over all 11,360,875 shares.
• The firm also holds shared dispositive power over 11,360,875 shares.
• This filing is an Amendment No. 1 to a Schedule 13G, with the event date requiring the filing being March 31, 2025.

Sentiment

Score: 5

Explanation: Neutral, as a Schedule 13G is a factual disclosure of ownership and does not contain performance or forward-looking statements from the issuer.

Industry Context

This Schedule 13G filing is a standard regulatory disclosure indicating a significant institutional investment by Jennison Associates LLC, a major asset manager, in Arcutis Biotherapeutics Inc., a publicly traded company. Such disclosures provide transparency regarding large ownership stakes in public companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity of the stock.

Key Dates

Keywords

Arcutis Biotherapeutics, Jennison Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser, Biotechnology, Pharmaceuticals